Cliff Asness's TBPH Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 47,820 shares of Theravance Biopharma, Inc. (TBPH) worth $812,940, representing 0.00% of the portfolio. First purchased in 2014-Q4, this short-term holding has been held for 8 quarters.
Based on 13F filings, Cliff Asness has maintained this position in TBPH for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 20,463 shares. Largest reduction occurred in Q1 2015, reducing 15,236 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Theravance Biopharma (TBPH) Holding Value Over Time
Track share changes against reported price movement
Quarterly Theravance Biopharma (TBPH) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +20,463 | Add 74.80% | 47,820 | $17.00 |
| Q1 2026 | +2,673 | Add 10.83% | 27,357 | $16.23 |
| Q4 2025 | +5,849 | Add 31.05% | 24,684 | $18.71 |
| Q3 2025 | +6,586 | Add 53.77% | 18,835 | $14.60 |
| Q2 2025 | +979 | Add 8.69% | 12,249 | $11.03 |
| Q1 2025 | +11,270 | New Buy | 11,270 | $8.93 |
| Q1 2015 | -15,236 | Sold Out | 0 | $0.00 |
| Q4 2014 | +15,236 | New Buy | 15,236 | $14.90 |
Cliff Asness's Theravance Biopharma Investment FAQs
Cliff Asness first purchased Theravance Biopharma, Inc. (TBPH) in Q4 2014, acquiring 15,236 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Theravance Biopharma, Inc. (TBPH) for 8 quarters since Q4 2014.
Cliff Asness's largest addition to Theravance Biopharma, Inc. (TBPH) was in Q2 2026, adding 47,820 shares worth $812,940.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 47,820 shares of Theravance Biopharma, Inc. (TBPH), valued at approximately $812,940.
As of the Q2 2026 filing, Theravance Biopharma, Inc. (TBPH) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Theravance Biopharma, Inc. (TBPH) was 47,820 shares, as reported at the end of Q2 2026.